Screening for HIV-associated distal-symmetric polyneuropathy inCDC-classification stages 1, 2 and 3

Husstedt, Ingo W.; Evers, Stefan; Reichelt, D.; Grotemeyer, Karl-Heinz; Kammer-Suhr, B.; Böckenholt, S.; Heese, Curt

doi:10.1034/j.1600-0404.2000.101003183.x

Cited by 13 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although to the authors' knowledge there is no definitive correlation with this study finding throughout literature, it is nevertheless known that HIV-PN can occur at any stage of the disease course. 32 A relevant study by Husstedt et al (2000), who studied the incidence of HIV-PN based on clinical and electrophysiological findings, reported signs of PN in 25% of stage-1 patients and in 45% of stage-3 patients. Respectively, neurophysiological changes in peripheral nerves were observed among 25% of stage-1 patients and in 45% of stage-3 patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece

et al. 2022

View full text Add to dashboard Cite

Background Peripheral neuropathy is among the most common complications among people with HIV with prevalence rates varying widely among studies (10–58%). Objective This study aims to assess the prevalence of HIV-associated peripheral neuropathy among HIV-positive people in Northern Greece monitored during the last 5-year period and investigate possible correlations with antiretroviral therapy, disease staging, and potential risk factors, as there is no prior epidemiological record in Greek patients. Methods Four hundred twenty patients were divided into a group with peripheral neuropathy ( n = 269), and those without ( n = 151). Peripheral neuropathy was assessed with a validated Peripheral Neuropathy Screening tool. Statistical analyses were performed with SPSS, were two-tailed, and p-value was set at 0.05. Results The incidence of peripheral neuropathy was estimated at 35.9%. Age was found to correlate with higher odds of developing HIV-peripheral neuropathy, rising by 4%/year. Females encountered 77% higher probability to develop peripheral neuropathy. Stage 3 of the disease associated with higher occurrence of peripheral neuropathy (96% as compared to stage-1 patients). Among patients with peripheral neuropathy, the duration of antiretroviral therapy was found to be longer than in those without. Conclusions Peripheral neuropathy remains one of the most common complications regardless of the antiretroviral-therapy type, indicating the involvement of other risk factors in its occurrence, such as the stage of the disease, age and gender. Therefore, the treating physician should screen patients as early and frequently as possible upon HIV-diagnosis to prevent the progression of this debilitating condition so that prolonged life-expectancy is accompanied by a good quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Respectively, neurophysiological changes in peripheral nerves were observed among 25% of stage-1 patients and in 45% of stage-3 patients. 33 The possible explanation given by the researchers was the impact of immunosuppression from stage 1-3.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Findings from Hawaii Aging with HIV revealed that low CD+4 count is a predictor of both cognitive and neurological status in HIV-1 infection [30] . Six-hundred and seventy patients were screened for distal symmetric HIV-associated polyneuropathy in a hospital-based study in Germany using nerve conduction studies and clinical neurologic examination during Centers for Disease Control (CDC) stages 1-3 [31] . Their results show stage related rising prevalence of distal symmetrical polyneuropathy, The prevalence of distal symmetrical polyneuropathy thus correlates with the degree of immunodeficiency.…”

Section: Cd4+ Countmentioning

confidence: 99%

Risk factors for HIV-distal symmetrical polyneuropathy: A review

Iyagba¹,

Onwuchekwa²

2017

J. Med. Res.

View full text Add to dashboard Cite

Objective: To review the risk factors of HIV distal symmetrical polyneuropathy. Methods: A MEDLINE search of the English-language literature using a combination of words (HIV, neuropathy, risk factors) was used to identify original studies, consensus statements, and reviews published in the last 20 years. Results: The various risk factors for HIV-distal symmetrical polyneuropathy. Conclusion: Some of these risk factors are amenable to treatment. Identification of these can go a long way in preventing or delaying the onset of DSPN in these patients thus improving their quality of life.

show abstract

Treatment for human immunodeficiency virus-related distal symmetrical polyneuropathy

Fialho¹,

Cornblath

2003

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Screening for HIV-associated distal-symmetric polyneuropathy inCDC-classification stages 1, 2 and 3

Cited by 13 publications

References 0 publications

Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece

Epidemiology of HIV-associated peripheral neuropathy in people living with human immunodeficiency virus infection in Greece

Risk factors for HIV-distal symmetrical polyneuropathy: A review

Treatment for human immunodeficiency virus-related distal symmetrical polyneuropathy

Contact Info

Product

Resources

About